Dactylitis and Enthesitis Data at Wks 24 and 52
| Variable | Secukinumab 300 mg | Secukinumab 150 mg | Secukinumab 75 mg | PBO |
|---|---|---|---|---|
| N=100 | N=100 | N=99 | N=98 | |
| Dactylitis at BL, n (%) | 46 (46.0) | 32 (32.0) | 33 (33.3) | 27 (27.6) |
| Dactylitis count at BL, mean | 3.6 | 4.4 | 3.0 | 2.7 |
| Dactylitis count, mean change from BL [95% CI] | ||||
| Wk 24 | −2.56 [−2.32, 0.89] | −2.53 [−3.16, 0.04] | −1.68 [−2.32, 0.89] | −0.97 |
| Wk 52 | −3.08 [−1.06, 1.11] | −3.11 [−2.31, −0.15] | −1.85 [−2.44, −0.07] | – |
| Enthesitis at BL, n (%) | 56 (56.0) | 64 (64.0) | 68 (68.7) | 65 (66.3) |
| Enthesitis count at BL, mean | 2.82 | 3.19 | 3.16 | 3.06 |
| Enthesitis count, mean change from BL [95% CI] | ||||
| Wk 24 | −1.68 [−1.27, 0.12] | −1.83 [−1.40, −0.04] | −1.38 [−0.95, 0.40] | −1.11 |
| Wk 52 | −1.68 [−0.38, 0.84] | −1.91 [−0.78, 0.43] | −1.50 [−1.00, 0.19] | – |
Symptoms in those patients with dactylitis/enthesitis at BL; dactylitis count from 20 digits (score of 0–20) and enthesitis count from 6 sites (score of 0–6); mixed-effect model repeated measures (MMRM) data.